PRLD Stock Gets Increased EPS Forecast from HC Wainwright

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of Prelude Therapeutics in a research report issued to clients and investors on Tuesday, October 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS and FY2027 earnings at ($0.67) EPS.

PRLD has been the topic of a number of other reports. Citigroup reaffirmed a “market outperform” rating on shares of Prelude Therapeutics in a research report on Wednesday. Wall Street Zen lowered shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Prelude Therapeutics in a research note on Thursday, September 17th. They set an “overweight” rating and a $12.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Prelude Therapeutics Price Performance

NASDAQ PRLD opened at $3.32 on Friday. The company has a 50 day simple moving average of $4.86 and a 200-day simple moving average of $4.53. The firm has a market capitalization of $264.94 million, a price-to-earnings ratio of -4.55 and a beta of 0.97. Prelude Therapeutics has a 52-week low of $1.16 and a 52-week high of $6.83.

Prelude Therapeutics (NASDAQ:PRLD) last released its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06. The business had revenue of $5.70 million for the quarter, compared to analysts’ expectations of $5.70 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in shares of Prelude Therapeutics during the 2nd quarter worth about $317,000. Spark Investment Management LLC acquired a new stake in shares of Prelude Therapeutics during the 2nd quarter valued at about $56,000. Bank of America Corp DE bought a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $127,000. ADAR1 Capital Management LLC bought a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $4,802,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $74,000. Hedge funds and other institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company uses cancer biology, medicinal chemistry and targeted drug-discovery approaches to identify small-molecule therapies designed to address genetic and molecular vulnerabilities in tumors.

Prelude’s investigational pipeline has included PRT3789, a selective SMARCA2 protein degrader being developed for cancers with SMARCA4 loss, and PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation for oncology applications.